Literature DB >> 10354399

Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.

H Matter1, W Schwab, D Barbier, G Billen, B Haase, B Neises, M Schudok, W Thorwart, H Schreuder, V Brachvogel, P Lönze, K U Weithmann.   

Abstract

A set of 90 novel 2-(arylsulfonyl)-1,2,3, 4-tetrahydroisoquinoline-3-carboxylates and -hydroxamates as inhibitors of the matrix metalloproteinase human neutrophil collagenase (MMP-8) was designed, synthesized, and investigated by 3D-QSAR techniques (CoMFA, CoMSIA) and X-ray structure analysis. Docking studies of a reference compound are based on crystal structures of MMP-8 complexed with peptidic inhibitors to propose a model of its bioactive conformation. This model was validated by a 1. 7 A X-ray structure of the catalytic domain of MMP-8. The 3D-QSAR models based on a superposition rule derived from these docking studies were validated using conventional and cross-validated r2 values using the leave-one-out method, repeated analyses using two randomly chosen cross-validation groups plus randomization of biological activities. This led to consistent and highly predictive 3D-QSAR models with good correlation coefficients for both CoMFA and CoMSIA, which were found to correspond to experimentally determined MMP-8 catalytic site topology in terms of steric, electrostatic, and hydrophobic complementarity. Subsets selected as smaller training sets using 2D fingerprints and maximum dissimilarity methods resulted in 3D-QSAR models with remarkable correlation coefficients and a high predictive power. This allowed to compensate the weaker zinc binding properties of carboxylates by introducing optimal fitting P1' residues. The final QSAR information agrees with all experimental data for the binding topology and thus provides clear guidelines and accurate activity predictions for novel MMP-8 inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354399     DOI: 10.1021/jm980631s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Synthetic mRNA splicing modulator compounds with in vivo antitumor activity.

Authors:  Chandraiah Lagisetti; Alan Pourpak; Tinopiwa Goronga; Qin Jiang; Xiaoli Cui; Judith Hyle; Jill M Lahti; Stephan W Morris; Thomas R Webb
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

2.  Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases.

Authors:  Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Lillian Onwuha-Ekpete; Kelli Harmon; Trista Robichaud; Rita Fuerst; Roma Stawikowska; Bjorn Steffensen; William Roush; Hector R Wong; Gregg B Fields
Journal:  J Med Chem       Date:  2017-04-19       Impact factor: 7.446

3.  Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.

Authors:  Roopa Kothapalli; Asif M Khan; Anupriya Gopalsamy; Yap Seng Chong; Loganath Annamalai
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

Review 4.  Structural aspects of the metzincin clan of metalloendopeptidases.

Authors:  F Xavier Gomis-Rüth
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

5.  Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol.

Authors:  Katarina Kores; Janez Konc; Urban Bren
Journal:  Pharmaceutics       Date:  2021-02-28       Impact factor: 6.321

6.  A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.

Authors:  Amit Gaggar; Patricia L Jackson; Brett D Noerager; Philip J O'Reilly; D Brent McQuaid; Steven M Rowe; J P Clancy; J Edwin Blalock
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.